MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317784 | Name: Escitalopram Oxalate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Escitalopram Oxalate is a furancarbonitrile that is one of the selective serotonin uptake inhibitors used as an antidepressant. As a selective serotonin reuptake inhibitor (SSRI), escitalopram blocks the reuptake of serotonin by neurons in the central nervous system (CNS), thereby potentiating CNS serotonergic activity. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.

Chemical Structure

Escitalopram Oxalate
Escitalopram Oxalate
CAS#219861-08-2 (oxalate)

Theoretical Analysis

MedKoo Cat#: 317784

Name: Escitalopram Oxalate

CAS#: 219861-08-2 (oxalate)

Chemical Formula: C22H23FN2O5

Exact Mass: 414.1591

Molecular Weight: 414.43

Elemental Analysis: C, 63.76; H, 5.59; F, 4.58; N, 6.76; O, 19.30

Price and Availability

Size Price Availability Quantity
200mg USD 250.00 2 Weeks
1g USD 450.00 2 Weeks
5g USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
128196-01-0 (free base) 219861-08-2 (oxalate)
Synonym
Escitalopram Oxalate; Cipralex; Lexapro; (S)-Citalopram Oxalate; Citalopram; Cytalopram; S-(+)-Citalopram oxalate; NSC-758934; NSC758934; NSC 758934; Lu 26-054-0; Lu-26-054-0
IUPAC/Chemical Name
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid
InChi Key
KTGRHKOEFSJQNS-BDQAORGHSA-N
InChi Code
InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)/t20-;/m0./s1
SMILES Code
CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM.
In vitro activity:
Treatment with 0.1, 0.2, 0.4 or 0.5 mM escitalopram oxalate for 24 h significantly reduced the viability of both A549 and H460 cells relative to those in the control group and the control cell line, BEAS-2B, respectively (Fig. 1A). Significantly reduced cell viability was also detected in A549 and H460 cells that were treated with 0.1, 0.2, 0.4 or 0.5 mM escitalopram oxalate for 48 h relative to those in the control group and the control cell line, BEAS-2B, respectively (Fig. 1B). Moreover, the invasive ability of BEAS-2B, A549 and H460 cells was evaluated as the number of cells that passed through a polycarbonate filter with 12 µm pores, the number of invaded in BEAS-2B, A549 and H460 cells that were treated with 0.05, 0.1, 0.2, 0.4 or 0.5 mM escitalopram oxalate for 24 h cells was significantly smaller than the corresponding number in the control group (Fig. 2). Reference: Oncol Lett. 2018 Mar; 15(3): 3376–3382. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778819/
In vivo activity:
Chronic hypoperfusion (2-VO) model was prepared and given escitalopram oxalate (experimental group) or PBS (control group) after 6 weeks. It was concluded that escitalopram oxalate could significantly improve the learning and memory ability of the rats with chronic cerebral ischemia probably by the VEGF-mediated angiogenesis. Reference: J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):514-518. https://pubmed.ncbi.nlm.nih.gov/26223919/
Solvent mg/mL mM
Solubility
DMSO 62.2 150.13
Water 20.0 48.26
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 414.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yuan I, Horng CT, Chen VC, Chen CH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells. Oncol Lett. 2018 Mar;15(3):3376-3382. doi: 10.3892/ol.2017.7687. Epub 2017 Dec 21. PMID: 29435082; PMCID: PMC5778819. 2. Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018 Feb;22(2):1167-1178. doi: 10.1111/jcmm.13372. Epub 2017 Nov 3. PMID: 29105282; PMCID: PMC5783874. 3. Ma L, Lu ZN, Hu P, Yao CJ. Neuroprotective effect of escitalopram oxalate in rats with chronic hypoperfusion. J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):514-518. doi: 10.1007/s11596-015-1462-x. Epub 2015 Jul 31. PMID: 26223919.
In vitro protocol:
1. Yuan I, Horng CT, Chen VC, Chen CH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells. Oncol Lett. 2018 Mar;15(3):3376-3382. doi: 10.3892/ol.2017.7687. Epub 2017 Dec 21. PMID: 29435082; PMCID: PMC5778819. 2. Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018 Feb;22(2):1167-1178. doi: 10.1111/jcmm.13372. Epub 2017 Nov 3. PMID: 29105282; PMCID: PMC5783874.
In vivo protocol:
1. Ma L, Lu ZN, Hu P, Yao CJ. Neuroprotective effect of escitalopram oxalate in rats with chronic hypoperfusion. J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):514-518. doi: 10.1007/s11596-015-1462-x. Epub 2015 Jul 31. PMID: 26223919.
1: Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679. PMID: 36350591; PMCID: PMC9647561. 2: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Escitalopram. 2022 Apr 18. PMID: 30000334. 3: Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-90. doi: 10.2165/00003088-200746040-00002. PMID: 17375980. 4: Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double- Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. 2022 Apr;111(4):886-895. doi: 10.1002/cpt.2487. Epub 2021 Nov 22. PMID: 34743319; PMCID: PMC9299061. 5: Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):121-8. doi: 10.1517/17425255.2014.863873. Epub 2013 Nov 30. PMID: 24289655. 6: Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Citalopram | Escitalopram (Celexa® | Lexapro®). 2023 Jan. PMID: 35951902. 7: Strous JFM. Psilocybine vergeleken met escitalopram bij depressie [Psilocybin compared with escitalopram for depression]. Ned Tijdschr Geneeskd. 2022 Jan 17;166:D6318. Dutch. PMID: 35138714. 8: Baldwin DS, Asakura S, Koyama T, Hayano T, Hagino A, Reines E, Larsen K. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta- analysis versus placebo. Eur Neuropsychopharmacol. 2016 Jun;26(6):1062-9. doi: 10.1016/j.euroneuro.2016.02.013. Epub 2016 Feb 27. PMID: 26971233. 9: Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. PMID: 35411074. 10: Blumenthal JA, Smith PJ, Jiang W, Hinderliter A, Watkins LL, Hoffman BM, Kraus WE, Liao L, Davidson J, Sherwood A. Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial. JAMA Psychiatry. 2021 Nov 1;78(11):1270-1278. doi: 10.1001/jamapsychiatry.2021.2236. PMID: 34406354; PMCID: PMC8374738. 11: Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018 Feb;22(2):1167-1178. doi: 10.1111/jcmm.13372. Epub 2017 Nov 3. PMID: 29105282; PMCID: PMC5783874. 12: Burke WJ. Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. doi: 10.1517/13543784.11.10.1477. PMID: 12387707. 13: Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Mar 1;78(3):270-280. doi: 10.1001/jamapsychiatry.2020.3643. PMID: 33237321; PMCID: PMC7702196. 14: Mathisen KK, Hardersen R. Escitalopram-associated rhabdomyolysis. Tidsskr Nor Laegeforen. 2023 Aug 24;143(12). English, Norwegian. doi: 10.4045/tidsskr.23.0093. PMID: 37668131. 15: Wang X, Fan Y, Li G, Li H. The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study. Int Clin Psychopharmacol. 2021 May 1;36(3):133-139. doi: 10.1097/YIC.0000000000000350. PMID: 33779577. 16: Yuan I, Horng CT, Chen VC, Chen CH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells. Oncol Lett. 2018 Mar;15(3):3376-3382. doi: 10.3892/ol.2017.7687. Epub 2017 Dec 21. PMID: 29435082; PMCID: PMC5778819. 17: Chawla N, Anothaisintawee T, Charoenrungrueangchai K, Thaipisuttikul P, McKay GJ, Attia J, Thakkinstian A. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022 Jan 19;376:e066084. doi: 10.1136/bmj-2021-066084. PMID: 35045991; PMCID: PMC8767458. 18: Khanna S, Chirinos RE, Venna S. Escitalopram oxalate (Lexapro)-induced acneiform eruption. J Am Acad Dermatol. 2012 Dec;67(6):e261-3. doi: 10.1016/j.jaad.2012.03.032. PMID: 23158626. 19: Rosa TFD, Machado CS, Serafin MB, Bottega A, Coelho SS, Foletto VS, Rampelotto RF, Lorenzoni VV, Mainardi A, Hörner R. Repurposing of escitalopram oxalate and clonazepam in combination with ciprofloxacin and sulfamethoxazole- trimethoprim for treatment of multidrug-resistant microorganisms and evaluation of the cleavage capacity of plasmid DNA. Can J Microbiol. 2021 Aug;67(8):599-612. doi: 10.1139/cjm-2020-0546. Epub 2021 Jan 22. PMID: 33481681. 20: Chen VC, Huang JY, Tzang BS, Hsu TC, McIntyre RS. Synergistic Effects of the Combinational Use of Escitalopram Oxalate and 5-Fluorouracil on the Inhibition of Gastric Cancer SNU-1 Cells. Int J Mol Sci. 2022 Dec 19;23(24):16179. doi: 10.3390/ijms232416179. PMID: 36555820; PMCID: PMC9781210.